| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/01/2008 | US20080102069 Using pertuzumab or combination trastuzumab and pertuzumab therapies to treat metastatic cell proliferative disorders |
| 05/01/2008 | US20080102068 Mitotic Kinesin Inhibitors |
| 05/01/2008 | US20080102067 Enhancing antigen-specific antibody titer in avian yolk utilizing adjuvant and gram positive bacteria |
| 05/01/2008 | US20080102066 Ultrapure transferrin for pharmaceutical compositions |
| 05/01/2008 | US20080102065 Erythropoietin receptor extended duration limited agonists |
| 05/01/2008 | US20080102064 Mixture comprising blood coagulation factor and serpin for use in prevention and treatment of blood disorders |
| 05/01/2008 | US20080102060 Methods of using bcl-2 for the therapeutic treatment and prevention of diseases |
| 05/01/2008 | US20080102040 Inhibition of factor b, the alternative complement pathway and methods related thereto |
| 05/01/2008 | US20080102027 Targer For B-Cell Disorders |
| 04/30/2008 | EP1916306A1 Recombinant vectors based on the modified vaccinia ankara (mva) virus as vaccines against leishmaniasis |
| 04/30/2008 | EP1916304A2 Antigenic polypeptides associated with multiple sclerosis and uses |
| 04/30/2008 | EP1916303A1 Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
| 04/30/2008 | EP1916259A1 Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
| 04/30/2008 | EP1916257A1 GD2 peptide mimotopes for anticancer vaccination |
| 04/30/2008 | EP1916020A2 Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient |
| 04/30/2008 | EP1916001A2 Human antibodies specific to KDR and uses thereof |
| 04/30/2008 | EP1916000A1 Use of measles virus nucleoprotein for treating atherosclerosis |
| 04/30/2008 | EP1915624A1 Amyloid beta receptor and uses thereof |
| 04/30/2008 | EP1915621A2 Methods and compositions for diagnosis and treatment of viral and bacterial infections |
| 04/30/2008 | EP1915456A1 Cancerous disease modifying antibodies |
| 04/30/2008 | EP1915455A1 Cancerous disease modifying antibodies |
| 04/30/2008 | EP1915398A2 Human anti-b7rp1 neutralizing antibodies |
| 04/30/2008 | EP1915397A2 Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| 04/30/2008 | EP1915396A2 Use of panton-valentine leukocidin for treating and preventing staphylococcus infections |
| 04/30/2008 | EP1915388A1 F11 receptor (f11r) antagonists as therapeutic agents |
| 04/30/2008 | EP1915176A2 Highly sensitive immunoassays and antibodies for detection of blood factor viii |
| 04/30/2008 | EP1915175A2 Direct and indirect effector cell protease receptor-1 (epr-1) inhibitors as antiplatelet agents |
| 04/30/2008 | EP1915174A1 Food products comprising probiotic micro-organisms and antibodies |
| 04/30/2008 | EP1915173A2 Rotavirus vaccine inducing heterotypic cross protection |
| 04/30/2008 | EP1915172A1 A vaccine composition comprising alpha-galactosylceramide as an adjuvant for intranasal administration |
| 04/30/2008 | EP1915151A2 Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors |
| 04/30/2008 | EP1615662B1 Transfection of blood cells with mrna for immunostimulation and gene therapy |
| 04/30/2008 | EP1212417B1 Promotion or inhibition of angiogenesis and cardiovascularization |
| 04/30/2008 | EP1058728B1 V-like domain binding molecules |
| 04/30/2008 | EP0730657B1 Composition for the in vivo production of therapeutic products |
| 04/30/2008 | CN101171261A Immunoglobulin fraction and process therefor |
| 04/30/2008 | CN101171035A Methods and compositions for modulating TWEAK and FN14 activity |
| 04/30/2008 | CN101171034A Humanized L243 antibodies |
| 04/30/2008 | CN101171033A Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
| 04/30/2008 | CN101171032A Use of native peptides and their optimized derivatives for vaccination |
| 04/30/2008 | CN101171031A Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| 04/30/2008 | CN101171018A Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| 04/30/2008 | CN101171010A Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| 04/30/2008 | CN101168743A Recombination baculoviral and its preparation method and application |
| 04/30/2008 | CN101168741A Lactococcus lactis food-sate secretion expression carrier and its preparing method and application |
| 04/30/2008 | CN101168062A Double-shell medicine sustained and controlled releasing carrier material and preparation method and application thereof |
| 04/30/2008 | CN101168055A Method for preparing novel influenza vaccine |
| 04/30/2008 | CN101168054A Fishes infectious spleen and kidney necrosis virus gene engineering vaccine and preparation method thereof |
| 04/30/2008 | CN101168053A Method for preparing self-body large intestine cancer vaccine |
| 04/30/2008 | CN100385002C Di- or oligomer of a dimer, trimer, quatrometer or pentamer of recombinant fusion proteins |
| 04/30/2008 | CN100384998C Method for preparing recombinant goose interleukin-2 protein and its application |
| 04/30/2008 | CN100384988C Chicken astrovirus type 2 |
| 04/30/2008 | CN100384985C Attenuated eel vibrio strain and its application |
| 04/30/2008 | CN100384878C Antibodies specific for human cd22 and their therapeutic anddiagnostic uses |
| 04/30/2008 | CN100384877C Antibody ('11c7') anti nogo a and its pharmaceutical use |
| 04/30/2008 | CN100384875C 蛋白质 Protein |
| 04/30/2008 | CN100384476C Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
| 04/30/2008 | CN100384424C Synergistic methods and compositions for treating cancer |
| 04/29/2008 | US7365221 Viricides; aids therapy |
| 04/29/2008 | US7365169 T-bet antibodies |
| 04/29/2008 | US7365168 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| 04/29/2008 | US7365156 PRO1316 polypeptides |
| 04/29/2008 | US7365155 Immunoregulator |
| 04/29/2008 | US7365154 Use as an immunogen to generate anti-integrin antibodies; a mimotope; vaccinating against angiogenic and metastatic diseases |
| 04/29/2008 | US7365054 Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| 04/29/2008 | US7364919 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides |
| 04/29/2008 | US7364893 infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene, US2 gene, UL47-like gene. ORF4 gene; polypeptide is derived from infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, and Marek's disease virus; vaccines |
| 04/29/2008 | US7364864 ANGE gene in atopy |
| 04/29/2008 | US7364859 Methods of using bioelastomers |
| 04/29/2008 | US7364745 Brucella melitensis strain deficient in the carboxyl-terminal proteolytic processing activity of a tail-specific protease caused by a nucleotide sequence deletion within a tspA gene; vaccine for swine, reindeer, cattle and humans; genetic engineering |
| 04/29/2008 | US7364744 Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV |
| 04/29/2008 | US7364743 Nucleotide sequence encoding PTD and CEA fusion protein, TAT-CEA fusion protein, anti-tumor vaccine and pharmaceutical composition for treating tumor comprising the fusion protein |
| 04/29/2008 | US7364742 Respiratory syncytial virus antibody comprising at least one heavy chain variable region and at least one light chain variable region having specific amino acid sequences; encoding complementary nucleic acids, vectors, host cells, transgenic animals or plants |
| 04/29/2008 | US7364741 Peptides of human Papilloma virus for use in human T cell response inducing compositions |
| 04/29/2008 | US7364740 Genetic deletions are used as markers to distinguish between pathogenic and avirulent strains such as Mycobacterium and Bacillus Calmette-Guerin (BCG); immunoassay; vaccines; attenuation, genetic engineering; immunogenic pure polypeptide encoded by a nucleotide sequence comprising open reading frame |
| 04/29/2008 | US7364739 Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of Haemophilus influenzae infections |
| 04/29/2008 | US7364738 Monoclonal antibodies to the CLFA protein and method of use in treating infections |
| 04/29/2008 | US7364737 Binding, neutralization respiratory syncytial virus antigen |
| 04/29/2008 | US7364736 Immmunoglobulin which prevents binding of osteoprotegerin ligand (OPGL) to osteoclast differentiation and activation receptor (ODAR) for treatment and prevention of bone, inflammatory, arthritic and autoimmune disorders |
| 04/29/2008 | US7364735 Method for diagnosis and treatment of haemophilia A patients with an inhibitor |
| 04/29/2008 | US7364734 Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist |
| 04/29/2008 | US7364733 antibodies that bind to Activated CD4+ T-cells (ACT-4) receptors; diagnostic or therapeutic use for immune disorders; selective suppression of immune response; allograft rejection, graft versus host disease, autoimmune diseases, allergies |
| 04/29/2008 | US7364732 Method for treating inflammation |
| 04/29/2008 | US7364731 Polypeptide variants |
| 04/29/2008 | US7364730 Human K+ channel and prognosing applications thereof |
| 04/29/2008 | US7364729 Method of inducing a CTL response |
| 04/29/2008 | US7364726 Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine |
| 04/29/2008 | CA2285136C Coccidiosis vaccines |
| 04/29/2008 | CA2273074C In ovo vaccination against newcastle disease |
| 04/27/2008 | CA2571805A1 Tissue targeted antigenic activation of the immune response to cancers |
| 04/24/2008 | WO2008049073A2 Compositions for the treatment of inflammation in the brain and other tissues |
| 04/24/2008 | WO2008048970A2 Synthetic antibodies |
| 04/24/2008 | WO2008048945A2 Conjugates of plasmodium falciparum surface proteins as malaria vaccines |
| 04/24/2008 | WO2008048680A2 Notch 2 signaling as a breast cancer suppressor pathway |
| 04/24/2008 | WO2008048670A2 Compositions and methods for modulating tlr14 activity |
| 04/24/2008 | WO2008048545A2 Molecules with reduced half-lives, compositions and uses thereof |
| 04/24/2008 | WO2008048519A2 Antibodies that bind cxcr7 epitopes |
| 04/24/2008 | WO2008048289A2 Salmonella based oral vaccines for anthrax |
| 04/24/2008 | WO2008048276A1 Detection of influenza virus type b |
| 04/24/2008 | WO2008047925A1 Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |